Summary
Stryker Corporation's first quarter 2021 report indicates a solid revenue increase of 10.2% to $3.95 billion, driven by strong performance in its Orthopaedics and Neurotechnology and Spine segments. The company experienced a notable rebound in Trauma and Extremities within Orthopaedics, alongside continued growth in Neurotechnology. Despite the overall revenue growth, net earnings saw a significant decrease of 38.7% to $302 million, translating to $0.79 per diluted share, down from $1.30 in the prior year. This decline is largely attributable to increased operating expenses, particularly higher selling, general, and administrative costs, and a substantial rise in amortization of intangible assets, primarily due to the acquisition of Wright Medical in late 2020. Operationally, the company navigated ongoing challenges from the COVID-19 pandemic, which continued to impact elective procedures. However, signs of recovery were observed towards the end of the quarter, especially in the United States and Asia Pacific. Stryker's financial position remains robust, with a healthy cash balance of $2.24 billion and strong liquidity, enabling continued investment in growth initiatives and debt management. Investors should note the strategic acquisition of Wright Medical is beginning to impact financial metrics, particularly through increased amortization expenses, while also contributing to segment growth.
Financial Highlights
51 data points| Revenue | $3.95B |
| Cost of Revenue | $1.44B |
| Gross Profit | $2.51B |
| R&D Expenses | $288.00M |
| SG&A Expenses | $1.57B |
| Operating Expenses | $2.05B |
| Operating Income | $459.00M |
| Net Income | $302.00M |
| EPS (Basic) | $0.80 |
| EPS (Diluted) | $0.79 |
| Shares Outstanding (Basic) | 376.30M |
| Shares Outstanding (Diluted) | 381.70M |
Key Highlights
- 1Total net sales increased by 10.2% to $3.95 billion, compared to $3.59 billion in Q1 2020, with international sales showing a significant 23.7% increase.
- 2The Orthopaedics segment experienced strong growth, with net sales up 21.4% to $1.48 billion, driven by a 63.1% surge in Trauma and Extremities products.
- 3Net earnings decreased by 38.7% to $302 million ($0.79 per diluted share) from $493 million ($1.30 per diluted share) in the prior year, primarily due to increased operating expenses and amortization.
- 4Selling, general, and administrative expenses rose significantly by 18.4%, impacting profitability.
- 5Amortization of intangible assets increased by 53.4% to $181 million, largely due to the acquisition of Wright Medical.
- 6The company maintained a strong liquidity position with $2.24 billion in cash and cash equivalents and $5.03 billion in net working capital.
- 7Stryker has suspended its share repurchase program through 2021, focusing resources elsewhere.